**pInhibition of Hepatitis C Virus Replication by Chalepin and Pseudane IX Isolated
from *Ruta angustifolia* leaves**

Tutik Sri Wahyuni^{1,2}, Aty Widyawaruyanti², Maria Inge Lusida³, Achmad Fuad², Soetjipto³,
Hiroyuki Fuchino⁴, Nobuo Kawahara⁴, Yoshitake Hayashi⁵, Chie Aoki¹, Hak Hotta^{1*}

¹Division of Microbiology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-
cho, Chuo-ku, Kobe, 650-0017, Japan.

²Department of Pharmacognocoy and Phytochemistry, Faculty of Pharmacy, Airlangga
University, Jl. Dharmawangsa Dalam, Surabaya, 60286, Indonesia.

³Institute of Tropical Disease, Airlangga University, Jl. Mulyorejo, Surabaya, 60115,
Indonesia.

⁴Research Center for Medicinal Plant Resources, National Institute of Biomedical Innovation,
1-2 Hachimandai, Tsukuba, Ibaraki, 305-0843, Japan.

⁵Division of Infectious Disease Pathology, Kobe University Graduate School of Medicine, 7-
5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.

*Corresponding author: Tel: +81-78-382-5500; Fax: +81-78-382-5519.

E-mail address: hotta@kobe-u.ac.jp

Abstract

Hepatitis C virus (HCV) infection is highly prevalent among global populations, with an estimated number of infected patients being 170 million. Approximately 70-80% of patients acutely infected with HCV will progress to chronic liver disease, such as liver cirrhosis and hepatocellular carcinoma, which is a substantial cause of morbidity and mortality worldwide. New therapies for HCV infection have been developed, however, the therapeutic efficacies still need to be improved. Medicinal plants are promising sources for antivirals against HCV. A variety of plants have been tested and proven to be beneficial as antiviral drug candidates against HCV. In this study, we examined extracts, their subfractions and isolated compounds of *Ruta angustifolia* leaves for antiviral activities against HCV in cell culture. We isolated six compounds, chalepin, scopoletin, γ -fagarine, arborinine, kokusaginine and pseudane IX. Among them, chalepin and pseudane IX showed strong anti-HCV activities with 50% inhibitory concentration (IC_{50}) of 1.7 ± 0.5 and 1.4 ± 0.2 $\mu\text{g/ml}$, respectively, without apparent cytotoxicity. Their anti-HCV activities were stronger than that of ribavirin (2.8 ± 0.4 $\mu\text{g/ml}$), which has been widely used for the treatment of HCV infection. Mode-of-action analyses revealed that chalepin and pseudane IX inhibited HCV at the post-entry step and decreased the levels of HCV RNA replication and viral protein synthesis. We also observed that arborinine, kokusaginine and γ -fagarine possessed moderate levels of anti-HCV activities with IC_{50} values being 6.4 ± 0.7 , 6.4 ± 1.6 and 20.4 ± 0.4 $\mu\text{g/ml}$, respectively, whereas scopoletin did not exert significant anti-HCV activities at 30 $\mu\text{g/ml}$.

Keywords: Hepatitis C virus, *Ruta angustifolia*, Rutaceae, Post-entry inhibition, Alkaloid, Coumarin.

48 Chemical compounds studied in this article:

49 Chalepin (PubChem CID 119066)

50 Scopoletin (PubChem CID 5280460)

51 Arborinine (PubChem CID 5281832)

52 γ -Fagarine (PubChem CID 107936)

53 Kokusaginine (PubChem CID 10227)

54 Pseudane IX (PubChem data not available)

55

56 **1. Background**

57

58 Hepatitis C virus (HCV) is an enveloped virus that belongs to the *Hepacivirus* genus
59 within the *Flaviviridae* family. The viral genome is a single-stranded, positive-sense RNA of
60 9.6 kb with highly structured 5'- and 3'-untranslated regions [1, 2]. It encodes a polyprotein
61 precursor consisting of about 3,000 amino acid residues, which is cleaved by the host and
62 viral proteases to generate 10 mature proteins, such as core, E1, E2, a putative ion channel p7,
63 and nonstructural proteins NS2, NS3, NS4A, NS4B, NS5A and NS5B. The core, E1 and E2
64 are cleaved off by the signal peptidase and signal peptide peptidase of the host cell and,
65 together with the viral genome, form the virus particles. The E1 and E2 glycoproteins are
66 responsible for binding to a number of different virus receptor molecules on the cell surface,
67 such as scavenger receptor class B type I, CD81, claudin 1 and occludin. On the other hand,
68 nonstructural proteins play crucial roles in virus replication. NS2 possesses a metalloprotease
69 activity that mediates cleavage between NS2 and NS3. After this cleavage takes place, NS3
70 exerts a serine protease activity that is responsible for the cleavage at the remaining cleavage
71 sites of the polyprotein. NS3 also possesses a helicase activity in its C-terminal domain,
72 which is required for viral RNA replication. NS4A stabilizes NS3 by forming a complex with
73 it and also acts as an inducer of membrane alterations. NS4B is a hydrophobic protein and is
74 involved in the membranous web formation, a characteristic feature of HCV-infected cells.
75 NS5A is a phosphoprotein with versatile functions and is required for viral RNA replication
76 and particle assembly [1, 3]. NS5B possesses an RNA-dependent RNA polymerase activity.
77 It is known that the HCV replication cycle is linked to the lipid metabolism of the host cells.
78 It should also be noted that the HCV genome exhibits a considerable degree of sequence
79 heterogeneity, based on which HCV is currently classified into 7 genotypes (1 to 7) and more
80 than 70 subtypes (1a, 1b, 2a, 2b, etc.) [4].

HCV infection is highly prevalent among global populations, especially in Africa and Asia, with an estimated number of infected patients being 170 million worldwide. Approximately 3 million people are newly infected with HCV worldwide every year [3, 5]. Seventy to 80% of newly infected patients progress to chronic infection. Patients with chronic HCV infection have a high risk to develop severe liver diseases such as cirrhosis and hepatocellular carcinoma, and also to develop extra hepatic manifestations, including glucose and lipid metabolic disorders [6, 7]. A standard care of HCV infection using pegylated interferon (Peg-IFN)- α and ribavirin can achieve sustained virological response (SVR) in ca. 50% of patients infected with HCV genotype 1 or 4 [5]. Triple combination therapy using Peg-IFN- α , ribavirin and an NS3 protease inhibitor increased the SVR rate to 70 to 80%. Moreover, recent approval of other direct-acting antivirals (DAA), including NS5A inhibitors, can further improve the SVR rate. However, they are not equally effective for all of the seven HCV genotypes and, more importantly, serious adverse effects are observed with some patients [5, 8]. This highlights the need for a new alternative and/or complementary agent(s) for treatment of HCV.

A wide variety of medicinal plants and their phytochemical constituents have been reported to inhibit HCV infection. For example, an extract of *Phyllanthus amarus* root significantly inhibited HCV NS3 protease with a 50% inhibitory concentration (IC₅₀) of 5 μ g/ml whereas *P. amarus* leaves inhibited HCV NS5B polymerase with the same IC₅₀ value [9]. We tested ethanol extracts of Indonesia plants for their anti-HCV activities and reported that *Toona sureni* leaves, *Melicope latifolia* leaves, *Melanolepis multiglandulosa* stem and *Ficus fistulosa* leaves possessed anti-HCV activities [10]. We also reported that extracts of *Glycyrrhiza uralensis* root and isolated compounds, such as glycycomarin, glycerin, glycyrol, and liquiritigenin, and extracts of *Morinda citrifolia* leaves, an isolated compound, pheophorbide a, and its related compound, pyropheophorbide a, exhibited anti-HCV activities

[11, 12]. Likewise, silymarin, iridoid, epigallocatechin-3-gallate were reported to inhibit HCV infection at the entry step while diosgenin, luteolin, quercetin, 3-hydroxy caruilignan C, excoecariphenol D and apigenin at the post-entry step [13, 14]. Although a number of novel antivirals against HCV are being developed, further studies are still needed to identify a safer, more effective and cheaper anti-HCV substance(s). Medicinal plants are a good target for the study.

Ruta angustifolia belongs to the Rutaceae family. Plants in the *Ruta* genus have been used as traditional remedy, such as antiseptics, antihelminthics and anti-inflammatory, wound-healing and pain-relief drugs, to cure malconditions during pregnancy and disorders in the gastrointestinal, respiratory, nervous, skin and musculoskeletal systems [15]. In Indonesia, *R. angustifolia* has been known as traditional medicine for liver disease and jaundice. It contains coumarin, alkaloid and flavonoid compounds. Angustifolin and four aromatic derivatives, moskachan A, B, C and D, have been identified as constituents of *R. angustifolia* [16, 17]. In this study, we examined the anti-HCV activities of extracts from *R. angustifolia* and its constituents.

2. Materials and methods

2.1. Cells and viruses

Huh7.5 cells and the plasmid pFL-J6/JFH1 to produce the J6/JFH1 strain of HCV genotype 2a [18] were kindly provided by Dr. C. M. Rice, The Rockefeller University, New York, NY, USA. Huh7.5 cells were cultivated in Dulbecco's modified Eagle's medium (Wako, Osaka, Japan) supplemented with fetal bovine serum (Biowest, Nuaille, France), non-essential amino acids (Invitrogen, Carlsbad, CA), penicillin (100 IU/ml) and streptomycin (100 µg/ml) (Invitrogen). Cells were grown at 37°C in a 5% CO₂ incubator.

2.2. Collection, extraction, fractionation and compound isolation of *R. angustifolia* leaves

R. angustifolia leaves were collected at Lembang, a mountain area of the West Java region, Indonesia. The collected samples were verified by botanical researchers at Purwadadi Botanical Garden, Purwadadi, Indonesia. Leaves of the plants were dried at room temperature, pulverized and extracted by means of two different extraction procedures; (i) 96% ethanol and (ii) *n*-hexane, dichloromethane and methanol, successively. Maceration process was repeated over 3 days. The obtained filtrates were concentrated under reduced pressure to yield ethanol, *n*-hexane, dichloromethane and methanol extracts. The dichloromethane extract was subjected to the open column chromatography with silica gel (development solvent: gradient of chloroform-methanol system). A bioactivity-positive fraction(s) was further fractionated under open column chromatography with silica gel and mobile phase gradient of hexane–ethyl acetate system. Based on thin layer chromatography (TLC) profiles, several fractions were combined and passed through an activated charcoal column and eluted by each 2 liters of methanol (100%), 30% of chloroform-methanol, and chloroform (100%) [19]. Each fraction was concentrated *in vacuo* and further subfractionated by recycling high-performance liquid chromatography (HPLC) (solvent system: 100% methanol, column: GS-320 + GS-310, 21.5 mm ID x 1000 mm, flow rate: 5.0 ml/min, detection: UV 210 nm) and preparative HPLC (column: Waters XBridge C18 10 x 250 mm, solvent system: gradient solvent of 0.1% Trifluoroacetic acid (TFA) – Acetonitrile, flow rate: 2.5 ml/min, column temperature: 30°C). Preparative HPLC was run on JASCO LC-2000 plus series. Recycling preparative HPLC was performed on a Japan Analytical Industry LC-908W.

To determine the structure of the isolated compounds, liquid chromatography-mass spectrometry (LC-MS), ¹H-nuclear magnetic resonance (NMR) and ¹³C-NMR analyses were performed. ¹H- and ¹³C-NMR spectra were measured with BRUKER Ascend 600

spectrometer (600MHz). LC-MS was performed with a Thermofischer Scientific Orbitrap Elite equipped with an electrospray ionization (ESI) source [20].

2.3. Analysis of anti-HCV activities

R. angustifolia extracts and isolated compounds were dissolved in dimethyl sulfoxide (DMSO) to obtain stock solutions at a concentration of 100 mg/ml. The stock solutions were stored at -20°C until used. Ribavirin was purchased (Sigma-Aldrich, Steinheim, Germany) and used as a positive control.

Huh7.5 cells were seeded in 24-well plates (1.9×10^5 cells/well). A fixed amount of the J6/JFH1-P47 strain of HCV genotype 2a [10, 21], with a multiplication of infection (MOI) of 0.5 focus-forming units (ffu)/cell, was mixed with serial dilutions of the extracts (100, 30, 10, 1 and 0.1 $\mu\text{g/ml}$) and compounds (30, 10, 3, 1 and 0.1 $\mu\text{g/ml}$), and inoculated to the cells. After 2 hours, the cells were washed with medium to remove the residual virus and further incubated in the medium containing the same concentrations of the test samples as those during virus inoculation.

Time-of-addition experiments were performed to assess the mode of action of the samples, as described previously [10-12]. In brief, three sets of experiments were done in parallel. (i) To assess the antiviral effect at the entry step, the mixture of HCV and a sample was inoculated to the cells. After virus adsorption for 2 hours, the residual virus and the sample were removed, and cells were refed with fresh medium without the sample for 46 hours. (ii) To assess the antiviral effect at the post-entry step, HCV was inoculated to the cells in the absence of the sample. After virus adsorption for 2 hours, the residual virus was removed and cells were refed with fresh medium containing the sample for 46 hours. (iii) As a positive control, HCV mixed with the sample was inoculated to the cells. After virus adsorption for 2 hours, the residual virus and the sample were removed, and cells were refed

with fresh medium containing the sample for 46 hours. Culture supernatants were obtained at 1 and 2 days post-infection (dpi) and titrated for virus infectivity [21]. Virus and cells treated with medium containing 0.1% DMSO served as a control. The percent inhibition of virus infectivity by the samples was calculated by comparing to the control using SPSS probit analysis, and IC₅₀ values were determined.

2.4. Real-time quantitative RT-PCR

Total RNA was extracted from the cells using a ReliaPrep RNA cell miniprep system (Promega, Madison, WI) according to the manufacturer's instructions. One µg of total RNA was reverse transcribed using a GoScript Reverse Transcription system (Promega) with random primers and subjected to quantitative real-time PCR analysis using SYBR Premix Ex Taq (TaKaRa, Kyoto, Japan) in a MicroAmp 96-well reaction plate and an ABI PRISM 7500 system (Applied Biosystems, Foster City, CA). The primers used to amplify an NS5A region of the HCV genome were 5'-AGACGTATTGAGGTCCATGC-3' (sense) and 5'-CCGCAGCGACGGTGCTGATAG-3' (antisense). As an internal control, human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene expression levels were measured using primers 5'-GCCATCAATGACCCCTTCATT-3' (sense) and 5'-TCTCGCTCCTGGAAGATGG-3' (antisense).

2.5. Immunoblotting

Cells were lysed and separated with SDS-polyacrylamide gel electrophoresis as described previously [10, 11]. The samples were transferred onto a polyvinylidene difluoride membrane (Millipore, Bedford, MA), which was then incubated with the respective primary antibodies. The primary antibodies used were mouse monoclonal antibodies against HCV NS3 and GAPDH (Millipore). Horseradish peroxidase-conjugated goat anti-mouse

immunoglobulin (Invitrogen) was used to visualize the respective proteins by means of an enhanced chemiluminescence detection system (ECL; GE Healthcare, Buckinghamshire, UK). The relative band intensity was quantified using densitometry analysis with ImageJ software. The NS3 protein expression levels were normalized to their respective GAPDH protein levels.

2.6. WST-1 assay for cytotoxicity

WST-1 assay was performed as described previously [10]. In brief, Huh7.5 cells in 96-well plates were treated with serial dilutions of the test samples or 0.1% DMSO as a control for 48 hours. After the treatment, 10 μ l of WST-1 reagent (Roche, Mannheim, Germany) was added to each well and cells were cultured for 4 hours. The WST-1 reagent is absorbed by the cells and converted to formazan by mitochondrial dehydrogenases. The amount of formazan, which correlates with the number of living cells, was determined by measuring the absorbance of each well using a microplate reader at 450 nm and 630 nm. Percent cell viability compared to the control was calculated for each dilution of substances and 50% cytotoxic concentration (CC₅₀) values were determined by SPSS probit analysis.

3. Results

3.1. Bioactivity-guided fractionation and purification of extracts from *R. angustifolia* leaves and isolation of compounds

Dried and pulverized *R. angustifolia* leaves were extracted with ethanol, *n*-hexane, dichloromethane and methanol as described in the Material and methods section, and examined for antiviral activities against the J6/JFH1-P47 strain of HCV genotype 2a [10, 21]. The results revealed that the dichloromethane extract of *R. angustifolia* leaves had potent anti-HCV activity with IC₅₀ of 1.6 ± 0.3 μ g/ml (Table 1). The dichloromethane extract was

further purified by open column chromatography to obtain 6 fractions, of which fraction 4 showed potent anti-HCV activity with IC_{50} of 0.7 $\mu\text{g/ml}$ (Table 2). Fraction 4 was further fractionated under open column chromatography with silica gel and mobile phase gradient of hexane–ethyl acetate system to obtain 29 fractions. Based on the TLC profile, some of the subfractions were combined and 4 groups of subfractions were passed through an activated charcoal column, which were eluted by each 2 liters of 100% methanol, 30% chloroform-methanol and 100% chloroform to give 3 fractions (a, 100% methanol; b, 30% chloroform-methanol; c, 100% chloroform) [19]. Each fraction was concentrated in vacuo. Fraction 1a was subjected to recycling HPLC to afford F1a-1 (3.1 mg) and F1a-2 (96.7 mg), which were determined as an identical compound (compound 1). Fraction 2b was separated using preparative HPLC to obtain F2b-1 (compound 2), F2b-2 and F2b-3 (compound 3). Fraction 3c was separated by filtration method with methanol to yield F3c-1 (compound 4) and F3c-2, the latter of which was subjected to preparative HPLC to obtain 3c-2A (compound 5) and 3c-2B (compound 4). Fraction 4a was subjected to preparative HPLC to obtain F4a-3 (compound 6). The structures of the isolated compounds were determined by LC-MS and NMR analyses.

Compound 1 (100.7 mg) was isolated as colorless amorphous powder with a molecular formula of $C_{19}H_{22}O_4$ by orbitrap MS, m/z 315.15719 $[M+H]^+$ and was identified as chalepin by comparison with NMR literature data [22]. Compound 2 (5.0 mg) was a yellow amorphous powder with a molecular formula of $C_{10}H_9O_4$, m/z 193.04833 $[M+H]^+$ and was identified as scopoletin [23]. Compound 3 (3.0 mg) was identified as γ -fagarine [24], an alkaloid compound, which has a molecular formula of $C_{13}H_{12}O_3N$, m/z 230.07985 $[M+H]^+$. Compound 4 (28.7 mg) was identified as arborinine[23], another alkaloid compound with a molecular formula of $C_{16}H_{16}O_4N$, m/z 286.10952 $[M+H]^+$. Compound 5 (6.5 mg) with a molecular formula of $C_{14}H_{14}O_4N$ was identified as kokusaginine [23, 25], an alkaloid

compound. Compound 6 (3.7 mg) with a molecular formula of $C_{18}H_{26}ON$, m/z 272.20089 was identified as pseudane IX [26]. The structures of the compounds are shown in Fig. 1.

3.2. Anti-HCV activities of the isolated compounds

Anti-HCV activities of the isolated compounds were tested. Ribavirin, which has been widely used for the treatment of HCV infection, was used as a positive control. The results obtained revealed that chalepin (compound 1) and pseudane IX (compound 6) possessed strong anti-HCV activities, with IC_{50} being 1.7 ± 0.5 and 1.4 ± 0.2 $\mu\text{g/ml}$, respectively (Table 3). Their anti-HCV activities were stronger than that of ribavirin (2.8 ± 0.4 $\mu\text{g/ml}$). Also, γ -fagarine (compound 3), arborinine (compound 4) and kokusaginine (compound 5) showed weaker but significant anti-HCV activities, with IC_{50} being 20.4 ± 0.4 , 6.4 ± 0.7 and 6.4 ± 1.6 $\mu\text{g/ml}$, respectively. On the other hand, scopoletin (compound 2) did not show any significant inhibitory effect at the concentration of 30 $\mu\text{g/ml}$. Dose-dependent profiles of anti-HCV activities and cytotoxicity of those compounds are shown in Fig. 2.

3.3. Mode-of-action of anti-HCV activities of chalepin and pseudane IX

Time-of-addition experiments were performed to determine whether the compounds inhibit HCV at the entry or post-entry step [10]. Percent HCV inhibitions by chalepin and pseudane IX at the concentrations of 30, 10, 3, 1 and 0.1 $\mu\text{g/ml}$ were measured in the experiments where the treatment was done either during (at the entry step), after virus inoculation (at the post-entry step) or both (Fig. 3). The IC_{50} values of chalepin for treatment at the entry step, post-entry step and both were 26.7 ± 1.3 , 5.2 ± 0.7 and 1.7 ± 0.5 $\mu\text{g/ml}$, respectively. Also, those for pseudane IX were 11.5 ± 0.2 , 3.0 ± 0.9 and 1.4 ± 0.9 $\mu\text{g/ml}$, respectively. These results suggested that chalepin and pseudane IX inhibited HCV predominantly at the post-entry step.

3.4. Inhibition of HCV RNA replication and HCV protein synthesis by chalepin and pseudane IX

To further confirm that chalepin and pseudane IX inhibit HCV infection at the post-entry step of HCV life cycle, we investigated the effect of those compounds on HCV RNA replication, viral protein synthesis and infectious virus production. Real-time quantitative RT-PCR analysis revealed that chalepin and pseudane IX at 3 and 10 $\mu\text{g/ml}$ inhibited HCV RNA replication (Fig. 4A). Consistently, immunoblotting analysis demonstrated that both compounds inhibited HCV protein synthesis (Fig. 4B). We confirmed in the same experiment that they inhibited HCV production in the culture (Fig. 4C).

4. Discussion

Medicinal plants are good resources to search a novel drug candidate(s). A wide variety of phytochemicals that inhibit virus infections have been isolated and reported. In the present study, we examined the possible anti-HCV activity of *R. angustifolia* extracts and its constituents. *R. angustifolia* is widely distributed throughout the world and has been used as folk medicine for treatment of certain diseases. Plants of the genus *Ruta* have been commonly used in both ancient and modern medicine practices in the Mediterranean region to cure pulmonary diseases, rheumatic diseases and helminthic infections [15, 27]. A large number of chemical constituents have been isolate from the genus *Ruta*, such as coumarins, alkaloids, benzoquinones, flavone glycosides, sterols, triterpenoids, acridone alkaloids, stigmasterol, lupeol, 5-methoxyarborinine, 5-hydroxyarborinine, ostruthin, bergapten, psoralen, xanthotoxin, limonoid obacunone, isopimpinellin, integriquinolone, kokusaginine, dictamnine, furoquinolin alkaloid, xanthyletin and xanthoxyletin [28, 29]. It was also

reported that coumarin compounds are the major constituents of the plants in the Rutaceae family, with about two hundred different coumarins being identified [30, 31]. Specifically, four aromatic compounds, such as moskachans A, B, C and D have been identified from *R. angustifolia* [17]. Another study on a chloroform extract of aerial part of *R. angustifolia* identified angustifolin, alkaloid graveolin, scoparone and 6,7,8-trimethoxycoumarin [16].

In this study, *R. angustifolia* leaves were subjected to extraction in different polarity of solvents and antiviral activities of the extracts were examined against the J6/JFH1-P47 strain of HCV. The results revealed that a dichloromethane extract of *R. angustifolia* leaves possessed the most potent activity (Table 1), suggesting that a semi-polar compound(s) extracted by dichloromethane was involved in the anti-HCV activity. We further fractionated the dichloromethane extract to obtain 6 fractions. Anti-HCV assay showed that fraction 4 inhibited HCV with IC_{50} of 0.7 μ g/ml without apparent cytotoxicity (Table 2). As the TLC profile of the positive fractions suggested the presence of chlorophyll or its related substance(s) in this fraction (data not show), we used activated-charcoal in column chromatography to remove them. Finally, we isolated six compounds and determined their structures by combination of HPLC, LC-MS and NMR; they were chalepin, scopoletin, γ -fagarine, arborinine, kokusaginine, and pseudane IX. Chalepin and scopoletin are classified as coumarins while the remaining four (γ -fagarine, arborinine, kokusaginine and pseudane IX) are alkaloids.

Chalepin, which has been isolated from *R. chalepensis* [32], *Stauranthus perforates* [33], *Clausena anisata* [34] and *C. lansium* [35], belongs to furocoumarin compounds with furan ring fused to the coumarin structure. It was reported to possess antimicrobial activities against *Pseudomonas aeruginosa* and *Trichomonas* as well as anti-coagulant activities [34, 35]. However, there has been no report so far regarding its antiviral activity against HCV. To the best of our knowledge, the present study is the first to demonstrate anti-HCV activities of

chalepin with IC_{50} being $1.7 \pm 0.5 \mu\text{g/ml}$ ($5.4 \pm 0.5 \mu\text{M}$) (Table 3). It was reported that chalepin inhibited respiration of isolated rat liver mitochondria by 40% at the concentration of $16 \mu\text{M}$ ($5.0 \mu\text{g/ml}$) [36]. Under our experimental conditions using cultured cells, chalepin exerted only marginal cytotoxicity, if any, at $30 \mu\text{g/ml}$ (Fig. 2).

We have reported that other coumarin compounds, such as glycycomarin, glycyrin and glycyrol, possess anti-HCV activities, with IC_{50} of 8.8, 7.2, and $4.6 \mu\text{g/ml}$, respectively [11]. The basic structure (1,2-benzopyron) of coumarin appears to be important for binding to HCV [37]. Fourteen compounds out of 24 coumarin derivatives were reported to inhibit HCV NS5B RNA polymerase activities with IC_{50} values between 17 and $63 \mu\text{M}$. The activities of those compounds were influenced by the position of methylation or hydroxylation groups in the benzopyron ring [37]. Recently, benzimidazole derivatives of coumarins have been reported to possess increased inhibitory effect on RNA polymerase of HCV NS5B [38, 39]. On the other hand, scopoletin, which is the other coumarin isolated in the present study, did not inhibit HCV at the concentration of $30 \mu\text{g/ml}$ ($155 \mu\text{M}$). Scopoletin isolated from several plants, such as *Erycibe obtusifolia* Benth, *Aster tataricus* and *Foeniculum vulgare*, and its synthetic derivatives have been extensively studied [40]. Further detailed analyses of derivatives of chalepin and scopoletin would help us understand the structural basis of anti-HCV activity of chalepin and generate a more potent anti-HCV compound(s).

γ -fagarine, arborinine and kokusaginine, which are alkaloid compounds, showed moderate inhibition with IC_{50} of 20.4 ± 0.4 , 6.4 ± 0.7 and $6.4 \pm 1.6 \mu\text{g/ml}$, respectively (Table 3). These compounds have been isolated from several plants, including the Rutaceae family [41-44] and arborinine was previously reported to inhibit human rhinovirus with IC_{50} of $3.19 \mu\text{M}$ by virtual model [45]. Pseudane IX, another alkaloid, also known as 2-nonyl-4 (1H)-quinolone, 2-nonyl-4-hydroxyquinoline (NHQ) or 4-hydroxy-2-nonylquinolone [46], showed potent anti-HCV activities with IC_{50} of $1.4 \pm 0.2 \mu\text{g/ml}$ ($5.1 \pm 0.2 \mu\text{M}$) (Table 3). A wide

variety of quinolones have been used as antimicrobial, anticancer and antiallergenic agents. Quinolones are known as broad-spectrum antibacterial agents with the main structure of 1,4 dihydro-4-oxo-quinolinyl moiety. Quinolones inhibit prokaryotic type II topoisomerases through direct binding to bacterial chromosome, and likewise, it may bind to viral nucleic acids and/or nucleoprotein complexes to act as antivirals [47]. Quinolones consist of heterobicyclic aromatic compounds and the moiety of C₉H₉ at carbon number 2 of pseudane IX may play an important role in its activities. Quinolones have been reported to act as inhibitors of HCV NS5B RNA polymerase by binding to the allosteric site II (non-nucleoside inhibitor-site 2) of this protein [48]. Twelve fluoroquinolones derivatives were reported to inhibit HCV replication and HCV NS3 helicase activity in cultured cells. Among them, fleroxacin, difloxacin, ofloxacin, 8-quinolinol, enoxacin, lumifloxacin and flumiquine were reported to inhibit HCV with IC₅₀ of 3.8, 2.5, 2.4, 2.2, 1.0, 1.9 and 1.7 μ M, respectively [49].

The key steps in HCV life cycle include entry into the host cells, uncoating and replication of the viral genome, translation of virus proteins, and assembly and release of the virion [8, 18]. To determine the impact of active compounds on HCV life cycle, we conducted time-of-addition experiments. We observed that chalepin and pseudane IX exhibited their anti-HCV activities at the post-entry step, inhibiting HCV RNA replication and NS3 protein synthesis.

In conclusion, we have identified chalepin and pseudane IX as anti-HCV compounds. These compounds could be good candidates to develop novel anti-HCV drugs.

Acknowledgements

The authors are grateful to Dr. C. M. Rice (The Rockefeller University, New York, NY) for providing Huh-7.5 cells and pFL-J6/JFH1. This work was supported in part by Science and Technology Research Partnerships for Sustainable Development (SATREPS)

from Japan Science and Technology Agency (JST), Japan International Cooperation Agency (JICA) and the Ministry of Research and Technology (RISTEK), Republic of Indonesia. This work was also carried out as part of Japan Initiative for Global Research Network on Infectious Diseases (J-GRID), Ministry of Education, Culture, Sports, Science and Technology, Japan, and the Global Center of Excellence (G-COE) Program at Kobe University Graduate School of Medicine.

References

- [1] Rupp, D., Bartenschlager, R. Targets for antiviral therapy of hepatitis C. *Semin Liver Dis* 2014; 34: 9-21.
- [2] Moradpour, D., Penin, F., Rice, C.M. Replication of hepatitis C virus. *Nat Rev Microbiol* 2007; 5: 453-63.
- [3] Lange, C.M., Jacobson, I.M., Rice, C.M., Zeuzem, S. Emerging therapies for the treatment of hepatitis C. *EMBO Mol Med* 2014; 6: 4-15.
- [4] Gottwein, J.M., Scheel, T.K., Jensen, T.B., Lademann, J.B., Prentoe, J.C., Knudsen, M.L., et al. Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. *Hepatology* 2009; 49: 364-77.
- [5] Ireton, R.C., Gale, M., Jr. Pushing to a cure by harnessing innate immunity against hepatitis C virus. *Antiviral Res* 2014.
- [6] Shoji, I., Deng, L., Hotta, H. Molecular mechanism of hepatitis C virus-induced glucose metabolic disorders. *Front Microbiol* 2011; 2: 278.
- [7] Deng, L., Shoji, I., Ogawa, W., Kaneda, S., Soga, T., Jiang, D.P., et al. Hepatitis C virus infection promotes hepatic gluconeogenesis through an NS5A-mediated, FoxO1-dependent pathway. *J Virol* 2011; 85: 8556-68.

406 [8] Ploss, A., Dubuisson, J. New advances in the molecular biology of hepatitis C virus
 407 infection: towards the identification of new treatment targets. Gut 2012; 61 Suppl 1: i25-35.

408 [9] Ravikumar, Y.S., Ray, U., Nandhitha, M., Perween, A., Raja Naika, H., Khanna, N., et al.
 409 Inhibition of hepatitis C virus replication by herbal extract: *Phyllanthus amarus* as potent
 410 natural source. Virus Res 2011; 158: 89-97.

411 [10] Wahyuni, T.S., Tumewu, L., Permanasari, A.A., Apriani, E., Adianti, M., Rahman, A.,
 412 et al. Antiviral activities of Indonesian medicinal plants in the East Java region against
 413 hepatitis C virus. Virol J 2013; 10: 259.

414 [11] Adianti, M., Aoki, C., Komoto, M., Deng, L., Shoji, I., Wahyuni, T.S., et al. Anti-
 415 hepatitis C virus compounds obtained from *Glycyrrhiza uralensis* and other *Glycyrrhiza*
 416 species. Microbiol Immunol 2014; 58: 180-7.

417 [12] Ratnoglik, S.L., Aoki, C., Sudarmono, P., Komoto, M., Deng, L., Shoji, I., et al.
 418 Antiviral activity of extracts from *Morinda citrifolia* leaves and chlorophyll catabolites,
 419 pheophorbide a and pyropheophorbide a, against hepatitis C virus. Microbiol Immunol 2014;
 420 58: 188-94.

421 [13] Ashfaq, U.A., Idrees, S. Medicinal plants against hepatitis C virus. World J
 422 Gastroenterol 2014; 20: 2941-7.

423 [14] Calland, N., Dubuisson, J., Rouille, Y., Seron, K. Hepatitis C virus and natural
 424 compounds: a new antiviral approach? Viruses 2012; 4: 2197-217.

425 [15] Pollio, A., De Natale, A., Appetiti, E., Aliotta, G., Touwaide, A. Continuity and change
 426 in the Mediterranean medical tradition: *Ruta* spp. (rutaceae) in Hippocratic medicine and
 427 present practices. J Ethnopharmacol 2008; 116: 469-82.

428 [16] Del Castillo, J.B., Luis, F.R., Secundino, M. Angustifolin, a coumarin from *Ruta*
 429 *angustifolia*. Phytochemistry 1984; 23: 2095-6.

- 430 [17] Del Castillo, J.B., Secundino, M., Luis, F.R. Four aromatic derivatives from *Ruta*
431 *angustifolia*. Phytochemistry 1986; 25: 2209-10.
- 432 [18] Lindenbach, B.D., Evans, M.J., Syder, A.J., Wolk, B., Tellinghuisen, T.L., Liu, C.C., et
433 al. Complete replication of hepatitis C virus in cell culture. Science 2005; 309: 623-6.
- 434 [19] Fuchino, H., Sekita, S., Mori, K., Kawahara, N., Satake, M., Kiuchi, F. A new
435 leishmanicidal saponin from *Brunfelsia grandiflora*. Chem Pharm Bull 2008; 56: 93-6.
- 436 [20] Fuchino, H., Daikonya, A., Kumagai, T., Goda, Y., Takahashi, Y., Kawahara, N. Two
437 new labdane diterpenes from fresh leaves of *Leonurus japonicus* and their degradation during
438 drying. Chem Pharm Bull 2013; 61: 497-503.
- 439 [21] Bungyoku, Y., Shoji, I., Makine, T., Adachi, T., Hayashida, K., Nagano-Fujii, M., et al.
440 Efficient production of infectious hepatitis C virus with adaptive mutations in cultured
441 hepatoma cells. J Gen Virol 2009; 90: 1681-91.
- 442 [22] Nicoletti, M., Delle Monache, F., Marini-Bettolo, G.B. Carbon-13 spectral data of
443 prenylated coumarins. Planta Med 1982; 45: 250-1.
- 444 [23] Wu, T.-S., Shi, L.-S., Wang, J.-J., Iou, S.-C., Chang, H.-C., Chen, Y.-P., et al. Cytotoxic
445 and Antiplatelet Aggregation Principles of *Ruta Graveolens*. Journal of the Chinese Chemical
446 Society 2003; 50: 171-8.
- 447 [24] Min, Y.D., Kwon, H.C., Yang, M.C., Lee, K.H., Choi, S.U., Lee, K.R. Isolation of
448 limonoids and alkaloids from *Phellodendron amurense* and their multidrug resistance (MDR)
449 reversal activity. Arch Pharm Res 2007; 30: 58-63.
- 450 [25] Bodendiek, S.B., Mahieux, C., Hänsel, W., Wulff, H. 4-Phenoxybutoxy-substituted
451 heterocycles – A structure–activity relationship study of blockers of the lymphocyte
452 potassium channel Kv1.3. European Journal of Medicinal Chemistry 2009; 44: 1838-52.
- 453 [26] Somanathan, R., Smith, K.M. Synthesis of some 2-alkyl-4-quinolone and 2-alkyl-4-
454 methoxyquinoline alkaloids. Journal of Heterocyclic Chemistry 1981; 18: 1077-9.

455 [27] Kannan, R., Babu, U.V. Identity and pharmacognosy of *Ruta graveolens* Linn. *Anc Sci*
456 *Life* 2012; 32: 16-9.

457 [28] Wijeratne, E.M.K., Bandara, B.M.R., Gunatilaka, A.A.L., Tezuka, Y., Kikuchi, T.
458 Chemical Constituents of Three Rutaceae Species from Sri Lanka. *Journal of Natural*
459 *Products* 1992; 55: 1261-9.

460 [29] Mohan, P.S., Ramesh, M., Shanmugam, P. Studies on the Indian Rutaceae. *Chemical*
461 *Investigation of Limonia alata and Evodia lunu-ankenda.* *Journal of Natural Products* 1985;
462 48: 501-.

463 [30] Gray, A.I., Waterman, P.G. Coumarins in the Rutaceae. *Phytochemistry* 1978; 17: 845-
464 64.

465 [31] Milesi, S., Massot, B., Gontier, E., Bourgaud, F., Guckert, A. *Ruta graveolens* L.: a
466 promising species for the production of furanocoumarins. *Plant Science* 2001; 161: 189-99.

467 [32] Mohr, N., Budzikiewicz, H., El-Tawil, B.A.H., El-Beih, F.K.A. Further furoquinolone
468 alkaloids from *Ruta chalepensis*. *Phytochemistry* 1982; 21: 1838-9.

469 [33] Anaya, A.L., Macías-Rubalcava, M., Cruz-Ortega, R., García-Santana, C., Sánchez-
470 Monterrubio, P.N., Hernández-Bautista, B.E., et al. Allelochemicals from *Stauranthus*
471 *perforatus*, a Rutaceous tree of the Yucatan Peninsula, Mexico. *Phytochemistry* 2005; 66:
472 487-94.

473 [34] Emerole, G., Thabrew, M.I., Anosa, V., Okorie, D.A. Structure-activity relationship in
474 the toxicity of some naturally occurring coumarins-chalepin, imperatorin and
475 oxypeucedanine. *Toxicology* 1981; 20: 71-80.

476 [35] Adebajo, A.C., Iwalewa, E.O., Obuotor, E.M., Ibikunle, G.F., Omisore, N.O.,
477 Adewunmi, C.O., et al. Pharmacological properties of the extract and some isolated
478 compounds of *Clausena lansium* stem bark: anti-trichomonal, antidiabetic, anti-
479 inflammatory, hepatoprotective and antioxidant effects. *J Ethnopharmacol* 2009; 122: 10-9.

480 [36] Olorunsogo, O.O., Emerole, G.O., Malomo, S.O., Thabrew, M.I. Inhibition of
 481 mitochondrial respiration by chalepin, a naturally occurring furocoumarin. *Toxicol Lett* 1983;
 482 15: 323-7.

483 [37] Nichols, D.B., Leao, R.A., Basu, A., Chudayeu, M., de Moraes Pde, F., Talele, T.T., et
 484 al. Evaluation of coumarin and neoflavone derivatives as HCV NS5B polymerase inhibitors.
 485 *Chem Biol Drug Des* 2013; 81: 607-14.

486 [38] Neyts, J., De Clercq, E., Singha, R., Chang, Y.H., Das, A.R., Chakraborty, S.K., et al.
 487 Structure-activity relationship of new anti-hepatitis C virus agents: heterobicycle-coumarin
 488 conjugates. *J Med Chem* 2009; 52: 1486-90.

489 [39] Peng, X.M., Damu, G.L., Zhou, C. Current developments of coumarin compounds in
 490 medicinal chemistry. *Curr Pharm Des* 2013; 19: 3884-930.

491 [40] Liu, W., Hua, J., Zhou, J., Zhang, H., Zhu, H., Cheng, Y., et al. Synthesis and in vitro
 492 antitumor activity of novel scopoletin derivatives. *Bioorg Med Chem Lett* 2012; 22: 5008-12.

493 [41] Rethy, B., Zupko, I., Minorics, R., Hohmann, J., Ocsosvski, I., Falkay, G. Investigation
 494 of cytotoxic activity on human cancer cell lines of arborinine and furanoacridones isolated
 495 from *Ruta graveolens*. *Planta Med* 2007; 73: 41-8.

496 [42] Haque, M.M., Begum, S., Sohrab, M.H., Ahsan, M., Hasan, C.M., Ahmed, N., et al.
 497 Secondary metabolites from the stem of *Ravenia spectabilis* Lindl. *Pharmacogn Mag* 2013; 9:
 498 76-80.

499 [43] Cuca Suarez, L.E., Pattarroyo, M.E., Lozano, J.M., Delle Monache, F. Biological
 500 activity of secondary metabolites from *Peltostigma guatemalense*. *Nat Prod Res* 2009; 23:
 501 370-4.

502 [44] Veiga, T.A., King-Diaz, B., Marques, A.S., Sampaio, O.M., Vieira, P.C., da Silva, M.F.,
 503 et al. Furoquinoline alkaloids isolated from *Balfourodendron riedelianum* as photosynthetic
 504 inhibitors in spinach chloroplasts. *J Photochem Photobiol B* 2013; 120: 36-43.

505 [45] Rollinger, J.M., Schuster, D., Danzl, B., Schwaiger, S., Markt, P., Schmidtke, M., et al.
506 In silico target fishing for rationalized ligand discovery exemplified on constituents of *Ruta*
507 *graveolens*. *Planta Med* 2009; 75: 195-204.

508 [46] Heeb, S., Fletcher, M.P., Chhabra, S.R., Diggle, S.P., Williams, P., Camara, M.
509 Quinolones: from antibiotics to autoinducers. *FEMS Microbiol Rev* 2011; 35: 247-74.

510 [47] Richter, S., Parolin, C., Palumbo, M., Palu, G. Antiviral properties of quinolone-based
511 drugs. *Curr Drug Targets Infect Disord* 2004; 4: 111-6.

512 [48] Kumar, D.V., Rai, R., Brameld, K.A., Somoza, J.R., Rajagopalan, R., Janc, J.W., et al.
513 Quinolones as HCV NS5B polymerase inhibitors. *Bioorg Med Chem Lett* 2011; 21: 82-7.

514 [49] Khan, I.A., Siddiqui, S., Rehmani, S., Kazmi, S.U., Ali, S.H. Fluoroquinolones inhibit
515 HCV by targeting its helicase. *Antivir Ther* 2012; 17: 467-76.

516

517

Figure Legends

Fig. 1. Molecular structures of the compounds isolated from *R. angustifolia* leaves. Chalepin (compound 1); Scopoletin (compound 2); γ -Fagarine (compound 3); Arborinine (compound 4); Kokusaginine (compound 5); Pseudane IX (compound 6).

Fig. 2. Dose-dependent inhibition of HCV infection by isolated compounds and their cytotoxicity. Various concentrations of isolated compounds, chalepin (A), scopoletin (B), γ -fagarine (C), arborinine (D), kokusaginine (E) and pseudane IX (F), were mixed with an equal amount of HCV to obtain a final concentration of 30 to 0.1 μ g/ml and inoculated to Huh 7.5 cells (MOI = 0.5). After virus adsorption, the cells were cultured with the same concentrations of compounds for 46 hours. The culture supernatants were harvested and titrated for virus infectivity. Percent inhibitions of HCV infectivity by each compound are shown. In parallel, cytotoxicity of the compounds was measured by WST-1 assay. Con, control. The data represent means $\pm$ SEM of data from two independent experiments.

Fig. 3. Mode-of-action analysis of chalepin and pseudane IX. Huh7.5 cells infected with HCV were treated with various concentrations of chalepin (A) and pseudane IX (B) at different timings; (i) only during virus inoculation (entry), (ii) only after virus inoculation (post entry) and (iii) both during and after virus inoculation (both), with a total incubation time of 48 hours. Con, control. Percent inhibitions at each concentration and IC₅₀ values are shown. The data represent mean $\pm$ SEM of data from two independent experiments.

Fig. 4. Inhibition of HCV RNA replication, HCV protein synthesis and infectious virus production by chalepin and pseudane IX. (A) Huh7.5 cells infected with HCV (MOI = 2) and

543 treated with chalepin or pseudane IX (10 and 3 $\mu\text{g/ml}$) and the untreated control were
544 subjected to real-time quantitative RT-PCR analysis. HCV RNA levels were normalized to
545 GAPDH mRNA expression levels. Data represent mean $\pm$ SEM of data from two independent
546 experiments, and the value for the untreated control at 1 dpi was arbitrarily expressed as 1.
547 Chal, chalepin; Pseu, pseudane. *, $p<0.001$; †, $p<0.05$. (B) Levels of HCV NS3 protein
548 synthesis in the cells described in (A) were measured by immunoblotting analysis using anti-
549 NS3 monoclonal antibody at 1 and 2 dpi. GAPDH served as an internal control to verify
550 equal amounts of sample loading. Signal intensities of NS3 were normalized to the
551 corresponding GAPDH signal. (C) Virus infectivity in the culture supernatants of the cells
552 described in (A) was measured. *, $p<0.001$; †, $p<0.05$.

figure 1

Chalepin (1)

Scopoletin (2)

γ-Fagarine (3)

Arborinine (4)

Kokusaginine (5)

Pseudane IX (6)

figure 2

■ % HCV inhibition

▨ % Cell viability

figure 3

figure 4

Table 1. Anti-HCV activity (IC₅₀), cytotoxicity (CC₅₀) and selectivity index (SI) of *R. angustifolia* leaves extracts.

Sample	IC ₅₀ (µg/ml)	CC ₅₀ (µg/ml)	SI
Ethanol extract	3.0 ± 1.4 ^a	>100	>30.3
n-Hexane extract	15.6 ± 5.2	>100	> 6.4
Dichloromethane extract	1.6 ± 0.3	49.2 ± 3.6	30.8
Methanol extract	8.1 ± 2.0	>100	> 12.3

a, Mean ± SEM of data from two independent experiments.

Table 2. Anti-HCV activity (IC₅₀), cytotoxicity (CC₅₀) and selectivity index (SI) of fractions from a dichloromethane extract of *R. angustifolia* leaves.

Sample	IC ₅₀ (µg/ml)	CC ₅₀ (µg/ml)	SI
Fraction 1	>100 ^a	>100	n.a. ^b
Fraction 2	>100	>100	n.a. ^b
Fraction 3	>100	>100	n.a. ^b
Fraction 4	0.7	42.1	64.8
Fraction 5	>100	>100	n.a. ^b
Fraction 6	7.4	>100	>13.5

a, Not detectable at the concentration of 100 µg/ml.

b, Not applicable.

Table 3. Anti-HCV activity (IC₅₀), cytotoxicity (CC₅₀) and selectivity index (SI) of the isolated compounds.

Isolate code	Compound	IC ₅₀ (µg/ml)	CC ₅₀ (µg/ml)	SI
Compound 1	Chalepin	1.7 ± 0.5 ^a	14.0 ± 2.4	8.2
Compound 2	Scopoletin	>30 ^b	>30 ^b	n.a. ^c
Compound 3	γ-Fagarine	20.4 ± 0.4	>30 ^b	>1.5
Compound 4	Arborinine	6.4 ± 0.7	16.3 ± 6.2	2.5
Compound 5	Kokusaginine	6.4 ± 1.6	>30 ^b	>4.7
Compound 6	Pseudane IX	1.4 ± 0.2	26 ± 0.9	18.6
Positive control	Ribavirin	2.8 ± 0.4	>30 ^b	>10.7

a, Mean ± SEM of data from two independent experiments.

b, Not detectable at the concentration of 30 µg/ml.

c, Not applicable

graphical abstract